Lilac and Soin seek RNA biomarkers for spinal cord stimulation; Avidity Biosciences (RNA) cited
- Avidity Biosciences and similar RNA companies could use validated RNA biomarker workflows.
- These workflows bridge mechanistic biology with clinical development.
- They provide quantitative molecular endpoints to inform dosing, target engagement, and patient selection.
Objective molecular readouts for spinal cord stimulation take shape
PROVIDENCE/ DAYTON — Lilac Biosciences and Soin Neuroscience are launching a preclinical collaboration to test whether RNA expression changes can serve as objective biomarkers of response to spinal cord stimulation for chronic pain. The partnership focuses on transcripts tied to inflammation and neural signaling, seeking reproducible molecular signatures that could replace or augment subjective patient reports. Work begins immediately in defined animal neuromodulation models and aligns with ongoing large-animal spinal cord stimulation studies at Soin that use both clinical waveforms and next-generation investigational systems.
RNA signatures to quantify neuromodulation response
Under the agreement, Lilac conducts quantitative RNA profiling and data validation using its RNA analytical workflows while Soin provides investigational spinal cord stimulation devices and large-animal models. Studies vary stimulation parameters, waveforms and time courses to map how specific neuromodulation settings alter transcriptomic patterns in spinal tissue and peripheral samples. The Soin device is explicitly for investigational use and not FDA approved; the groups emphasize preclinical validation and independent replication before any human application.
If Lilac and Soin identify reproducible RNA readouts, the biomarkers could guide device design, provide objective endpoints for efficacy, and strengthen preclinical-to-clinical translation. Dr. Amol Soin, an interventional pain specialist, says molecular signatures would reduce reliance on subjective measures and limit bias in future human trials. For companies in the RNA therapeutics and diagnostics sector, including firms such as Avidity Biosciences, validated RNA biomarker workflows offer a potentially valuable bridge between mechanistic biology and clinical development by supplying quantitative molecular endpoints that inform dosing, target engagement and patient selection.
Study governance, data sharing and IP plans
The collaboration includes standardized sampling protocols, statistical validation milestones, joint publication plans and shared considerations for intellectual property and resources. Both parties say data sharing and reproducibility are central to determining whether RNA-based readouts can reach the level of regulatory-grade biomarkers.
Path to human studies remains conditional
Any move into human research or regulatory filings is contingent on robust, reproducible preclinical results and independent replication. Initial datasets will determine whether RNA profiling can serve as practical molecular biomarkers to support next-generation neuromodulation device development and more objective assessment of chronic pain therapies.